Radiotracers

GIGA researchers have developed the 18F-FB-mini-PEG-E[c(RGDyK)](2), 18F-FPRGD2, a radiopharmaceutical targeting the integrin αvβ3, a transmembrane heterodimeric receptor regulating cell interaction with the extracellular matrix (ECM). The interaction site of integrin αvβ3 with ECM is a tripeptide sequence arginine-glycine-aspartic acid (RGD) present in a wide range of ECM molecules including fibronectin, fibrinogen, von Willebrand factor, thrombospondin, vitronectin, tenascin, osteopontin and bone sialoprotein.

They have recently reported the osteoarticular uptake of 18F-FPRGD2 in a large cohort of 61 patients primarily studied for oncologic purposes. The results were the first showing the systematic analysis 18F-FPRGD2 uptake in the musculoskeletal system. Their data clearly identified a homogeneous binding of the 18F-FPRGD2 within structures that anatomically correspond to the cartilage surrounding the femoral head of an osteoarthritic hip. They have observed similar global fixation of the tracer on the entire degenerated disc.

Highlighting the role of integrins in osteoarthritis development opens the door to osteoarthritis diagnosis using in vivo non-invasive and quantitative imaging technology.

Looking for clinical advice or support, or preparing for a clinical study? We will help you set up a cost-effective and time-efficient study! Get in touch with our experts [info@b2h.be].

Related articles

PDC*line Pharma is GMP accredited by the Belgian Federal Agency for Medicines and Health Products (FAMHP) for its Quality Control and Release Activities for PDC*lung, a drug for lung cancer immunotherapy

Liège (Belgium), 21st January 2019. PDC*line Pharma is delighted to announce, that the company is now accredited by the Belgian Federal Agency for Medicines and Health Products (FAMHP) for the Quality Control and Release activities of its anticancer agent PDC*lung, intended for the treatment of patients with lung cancer.  PDC*line Pharma is developing a new

Read more
PDC*line Pharma is GMP accredited by the Belgian Federal Agency for Medicines and Health Products (FAMHP) for its Quality Control and Release Activities for PDC*lung, a drug for lung cancer immunotherapy

First Congress in Health Simulation

The Medical Simulation Center of the University of Liège organizes its first congress in Health Simulation: “Towards evidence-based simulation”. Event will be held on Thursday, March 28th, 2019 in the faculty of medicine amphitheatres of Liège University, located on Sart-Tilman campus. Several themes will be discussed: Evidence-based Innovations and advances in simulation Medical education –

Read more
First Congress in Health Simulation

New University Certificate for clinical trials

The Clinical Sciences Department of the Medicine Faculty of the University of Liège organizes from the academic year 2018-2019 a University Certificate in clinical trials. More information is available in this folder

Read more
New University Certificate for clinical trials